With the potential of antimicrobial resistance (AMR) taking our modern medicine practices back to the stone age, governments around the world need to face the threat head on.
Stephen Tindal, director of science and technology at Catalent Pharma Solutions discusses what methods can be used to classify a drug’s solubility and bridge the divide between disciplines during development phases.
John Erdner, product manager, aseptic fill-finish systems, SP Scientific PennTech, discusses the advances being made in vial processing to help reduce the risk of vial damage and particle contamination.
Powder processing company Hanningfield details its recent case study for natural medicine company Integria Healthcare. Here, Hanningfield discusses how it helped Integria find a solution for sieving its dry powders
Jared Kimble, life sciences product specialist consultant at DXC Technology, writes about how regulatory intelligence can be utilised by life science companies.
From AI to mHealth, Jim Streeter, global vice president life sciences product strategy Oracle Health Sciences give us his pharma predictions for next year.
As we enter the winter flu season, embracing more innovative diagnostics at the point of care (POC) could play a vital role in helping to address the burden which influenza places on public health services.
Partner and patent attorney at intellectual property firm, Withers & Rogers, Dr Nicholas Jones, discusses why drug companies should continue to pursue new medical patents in the future, despite recent examples of legal disputes.
Amplexor’s VP of strategy for life sciences Romuald Braun asks how growing pressure on regulatory data is changing the way firms manage it and what is the best bet exploiting the transformation for the benefit of their own businesses?
